Drugs · acquisition-cost intelligence
desvenlafaxine
Desvenlafaxine· ingredient desvenlafaxine· DESVENLAFAXINE SUCCINATE 50 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.44910
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other desvenlafaxine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Desvenlafaxine | $0.43775 | −$0.01140 |
| Desvenlafaxine | $0.44410 | −$0.00500 |
| Desvenlafaxine | $3.84 | +$3.39 |
| Pristiq Extended-Release | $13.95 | +$13.50 |
Medicare Part D coverage · CY2026
On 324 plan formularies · typical tier 2
Prior auth 0% · Step therapy 1% · Quantity limit 90% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.